Navigation Links
Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
Date:2/19/2008

a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, CollaRx(R) and Liquicoll(R). Innocoll 's lead product, Gentamicin Surgical Implant for the treatment and prevention of surgical site infections, is approved for sale in 49 countries in Europe, Latin America, Middle East, Africa and Asia and is marketed under the following trade names; COLLATAMP(R) G, COLLATAMP(R) EG, SULMYCIN(R) IMPLANT, GARAMYCIN(R) SCHWAMM, DURACOL(R), DURACOLL(R), GENTACOL(R), GENTACOLL(R), GARACOL(R), GARACOLL(R), and CRONOCOL(R). In 2005, Innocoll acquired the worldwide marketing rights for this product from Essex Chemis AG, an affiliated company of Schering-Plough Corporation (NYSE: SGP) and in August 2007 sold its marketing rights, with the exception of the US, to EUSA Pharma. Gentamicin Surgical Implant is currently in phase 3 development in the US for the prevention of surgical site infections. Other late stage pharmaceutical products in Innocoll's development pipeline include CollaRx Gentamicin Topical for the treatment and prevention of infected diabetic foot ulcers and CollaRx Bupivacaine Implant for the management of post-operative pain, both of which are currently in Phase 2 development. For more information, please visit http://www.innocollinc.com.


'/>"/>
SOURCE Innocoll, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
2. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
3. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
4. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
5. Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin
6. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
7. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
8. Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas
9. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
10. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
11. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... -- According to a new market research ... Device, Display, & Microprocessor/MCU), by Application (Imaging, Medical Therapeutics, ... - Global Forecast to 2020", published by MarketsandMarkets, the ... reach $56.50 Billion by 2020, growing at a CAGR ... 235 market data Tables and 71 Figures spread through ...
(Date:9/17/2014)... , Sept. 17, 2014  NuView Life ... global licensing and collaboration agreement with Otsuka Pharmaceutical ... NuView,s investigative genomic-based diagnostic biomarker to detect cancers ... includes all other future diagnostic-imaging applications. NuView retains ... therapeutic delivery and in-vitro urine screen applications. ...
(Date:9/17/2014)... , Sept. 17, 2014 Isis ... that it has earned a $4 million milestone ... ) associated with the initiation of a Phase ... multi-drug resistant (MDR), gram-negative bacterial infections.  The Phase ... to evaluate the efficacy and safety of plazomicin ...
Breaking Medicine Technology:Medical Electronics Market Worth $56.50 Billion by 2020 2Medical Electronics Market Worth $56.50 Billion by 2020 3Medical Electronics Market Worth $56.50 Billion by 2020 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 3NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 5Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 2Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 3
(Date:9/18/2014)... (PRWEB) September 18, 2014 Specialty ... in Westlake, OH, announces that they have achieved ... PowerServer, a Complete Certified Ambulatory EHR-certified system developed ... Specialty Teleradiology had a non MU compliant PACS ... their business grew from a niche in oncology ...
(Date:9/18/2014)... Doylestown, PA (PRWEB) September 18, 2014 ... month by successfully launching its first product a mere ... F PRIME™ is a high performance glycan release enzyme ... assurance, glycobiology research, and the basis for tissue pathology ... Bulldog Bio (Portsmouth, NH) for the North American market ...
(Date:9/18/2014)... 9Lover.com, an internationally well-known designer and leader in ... promotion for its maternity wedding outfits. Now, all the ... maternity wedding dresses on its website. , ... consumers. The company’s development manager believes the cheap maternity ... The current special offer will last until September 29, ...
(Date:9/17/2014)... 2014 Today, Fecbek, a leading dress manufacturer ... special occasion gowns. These are a lot of beautiful A-line ... new range. , A skirt is a tube- or ... or part of the legs. In the western world, skirts ... be a draped garment which is made out of a ...
(Date:9/17/2014)... Recently, UWDress.com, an innovative company that ... occasion outfits, has released its 2014 empire waist ... has launched a big sale for these new and ... deeply discounted rates, from 15 to 65 percent off. ... on using comfortable to wear materials. Its elegant items ...
Breaking Medicine News(10 mins):Health News:Specialty Teleradiology Attains Meaningful Use with PowerServer MU 2Health News:Specialty Teleradiology Attains Meaningful Use with PowerServer MU 3Health News:N-Zyme Scientifics Announces Successful Product Launch 2Health News:Discounted Maternity Wedding Dresses For 2014 Introduced By 9Lover.com 2Health News:Fecbek.com Has Recently Announced Its New Series of Delicate Special Occasion Gowns Online 2Health News:2014 Empire Waist Evening Dress Collection Now Unveiled At UWDress.com 2
... Sweden: Two trials presented at the Heart Failure Congress 2011, ... European Society of Cardiology (HFA of the ESC), will help ... heart failure (CHF) in whom telemedical management delivers benefits. ... Late Breaking Session 1 - revealed that telemonitoring showed significant ...
... By Steven Reinberg HealthDay Reporter , FRIDAY, ... benefits of robotic surgery on their websites without solid ... researchers report. In fact, four out of 10 ... robotic surgery is better than conventional surgery, an assertion ...
... May 21 (HealthDay News) -- As summer approaches and ... experts say. "We are not invincible when it ... an athletic trainer with the University of Tennessee at ... Medical and Science Advisory Board, in a news release ...
... chemotherapy is used to kill cancer cells, it can also ... bone marrow and blood cells, often limiting the ability to ... Cancer Research Center reported at today,s annual meeting of the ... one possible approach to reduce this toxic effect on bone ...
... York, NY (May 20, 2011)The American Federation for Aging Research ... 83 advanced fellows and junior faculty at 27 Centers of ... This effort, funded with support from the John A. Hartford ... create the cadre of academic leaders in geriatrics. As our ...
... , FRIDAY, May 20 (HealthDay News) -- Treating chronic ... and function, according to a new study. Prior research ... problems and reduced gray matter in brain areas that play ... pain, such as anxiety and depression. But it wasn,t clear ...
Cached Medicine News:Health News:Telemonitoring can improve overall survival of HF patients 2Health News:Telemonitoring can improve overall survival of HF patients 3Health News:Telemonitoring can improve overall survival of HF patients 4Health News:Telemonitoring can improve overall survival of HF patients 5Health News:Robotic Surgery Oversold on Hospital Websites, Study Contends 2Health News:Robotic Surgery Oversold on Hospital Websites, Study Contends 3Health News:Robotic Surgery Oversold on Hospital Websites, Study Contends 4Health News:Keeping Cool in the Heat 2Health News:Gene-modified stem cells help protect bone marrow from toxic side effects of chemotherapy 2Health News:AFAR announces the 2011 Hartford Scholars in Geriatric Medicine 2
100cc silicone evacuator with hubless flat drain and trocar...
Used following open gallbladder procedure to drain bile. Often attached to Bard bile bag....
Silicone Flat Hubless Drains...
Hubbed drains are made of translucent silicone and include a full-length X-ray opaque stripe....
Medicine Products: